No Data
Senseonics Stock Down Despite New FDA Approval for Eversense 365
BTIG Maintains Senseonics(SENS.US) With Hold Rating
Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years Older.
Express News | Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years Older
FDA Clearance Announcement Sends Small Cap Soaring
Senseonics Announces First CGM